Mizuho Maintains Bearish View on Relypsa (RLYP) Despite Q1 Top-Line Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Relypsa (RLYP) Financing Does Not Prevent 2016 Acquisition - Wedbush
May 9, 2016 10:40 AM EDTIn a note dated May 6, Wedbush analyst Liana Moussatos reiterated an Outperform rating while trimming her price target on Relypsa, Inc. (NASDAQ: RLYP) to $51.00 (from $52.00), saying the financing provides a runway into mid-2017 and does not prevent a 2016 acquisition.
Moussatos commented, "The recent $150MM debt financing alleviates 2016 cash... More
Debt Financing Buys Relypsa (RLYP) Time to Negotiate a Sale - Brean
May 5, 2016 10:11 AM EDTBrean Capital analyst Difei Yang reiterated a Buy rating and $26 price target on Relypsa, Inc. (NASDAQ: RLYP) as Q1 beat consensus estimates, though the commercial launch of Veltassa continues to be slow.
"While Veltassa is still attractive in the long... More
Relypsa (RLYP) Tops Q1 EPS by 20c
May 4, 2016 4:09 PM EDTRelypsa (NASDAQ: RLYP) reported Q1 EPS of ($1.26), $0.20 better than the analyst estimate of ($1.46). Revenue for the quarter came in at $12.4 million versus the consensus estimate of $6.88 million.
We made great progress in our first full quarter with Veltassa on the market. We saw solid month-over-month growth of prescriptions, reported early success with payers, including agreements with the two largest pharmacy benefit managers, and have had a positive reception from treating physicians, said John A. Orwin, president and chief executive officer of Relypsa. Yesterday, we announced a debt financing that will... More
